AML17 Trial results: maximum dosage of daunorubicin in AML
AML17 Trial results: maximum dosage of daunorubicin in AML
The future of haematopathology
Frontline therapy in young patients with myeloma
Cell of origin role in cancer stem cell and GBM phenotype
New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations
MINDACT breast cancer clinical trial: First results and impact on future trial design
BSH 2016: Expert discussion on front line care in CLL
BSH 2016: Expert discussion on idelalisib
Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance
Next-generation sequencing in the lymphoid malignancies
Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy
Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy